{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:45:54Z","timestamp":1790091954180,"version":"4.0.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82422013"],"award-info":[{"award-number":["82422013"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82400686"],"award-info":[{"award-number":["82400686"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370585"],"award-info":[{"award-number":["82370585"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2024ZD0530902"],"award-info":[{"award-number":["2024ZD0530902"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019537","name":"Science Fund for Distinguished Young Scholars of Hubei Province","doi-asserted-by":"publisher","award":["2024AFA073"],"award-info":[{"award-number":["2024AFA073"]}],"id":[{"id":"10.13039\/501100019537","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jlr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Lipid Research"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jlr.2025.100835","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T19:09:02Z","timestamp":1748545742000},"page":"100835","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Hepatoprotective drug screening identifies daclatasvir, a promising therapeutic candidate for MASLD by targeting PLIN2"],"prefix":"10.1016","volume":"66","author":[{"given":"Rui","family":"Shu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyi","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toujun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changjin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zifeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8432-6058","authenticated-orcid":false,"given":"Jiajun","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Gang","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongliang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jlr.2025.100835_bib1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.jlr.2025.100835_bib2","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1002\/hep.31150","article-title":"Epidemiological features of NAFLD from 1999 to 2018 in China","volume":"71","author":"Zhou","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jlr.2025.100835_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101092","article-title":"Dysregulated lipid metabolism links NAFLD to cardiovascular disease","volume":"42","author":"Deprince","year":"2020","journal-title":"Mol. Metab."},{"key":"10.1016\/j.jlr.2025.100835_bib4","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1210\/clinem\/dgab641","article-title":"Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: a 4.6-year cohort study in China","volume":"107","author":"Liang","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jlr.2025.100835_bib5","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.2337\/dc12-0033","article-title":"Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients","volume":"35","author":"Bozzetto","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jlr.2025.100835_bib6","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-G\u00f3mez","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jlr.2025.100835_bib7","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jlr.2025.100835_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jlr.2025.100835_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adl0998","article-title":"New government drug repurposing programs: opportunities and uncertainties","volume":"16","author":"Liddicoat","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jlr.2025.100835_bib10","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41569-022-00717-6","article-title":"Repurposing drugs to treat cardiovascular disease in the era of precision medicine","volume":"19","author":"Abdelsayed","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.jlr.2025.100835_bib11","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41581-024-00836-y","article-title":"Applications of SGLT2 inhibitors beyond glycaemic control","volume":"20","author":"O\u2019Hara","year":"2024","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.jlr.2025.100835_bib12","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1093\/eurheartj\/ehaa498","article-title":"Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial","volume":"41","author":"Tu\u00f1\u00f3n","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jlr.2025.100835_bib13","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1053\/j.gastro.2016.11.047","article-title":"Daclatasvir prevents hepatitis C virus infectivity by blocking transfer of the viral genome to assembly sites","volume":"152","author":"Boson","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jlr.2025.100835_bib14","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s40262-017-0624-3","article-title":"Daclatasvir: a review of preclinical and clinical pharmacokinetics","volume":"57","author":"Gandhi","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jlr.2025.100835_bib15","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jlr.2025.100835_bib16","doi-asserted-by":"crossref","first-page":"318","DOI":"10.2174\/1874467213666200116114919","article-title":"Daclatasvir and sofosbuvir mitigate hepatic fibrosis through downregulation of TNF-\u03b1\/NF-\u03baB signaling pathway","volume":"13","author":"Zakaria","year":"2020","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.jlr.2025.100835_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217751","article-title":"Treatment with direct-acting antivirals improves peripheral insulin sensitivity in non-diabetic, lean chronic hepatitis C patients","volume":"14","author":"Gastaldi","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jlr.2025.100835_bib18","doi-asserted-by":"crossref","first-page":"e1012","DOI":"10.1093\/infdis\/jiae210","article-title":"Hepatitis B virus and hepatitis C virus affect mitochondrial function through different metabolic pathways, explaining virus-specific clinical features of chronic hepatitis","volume":"230","author":"Selvamani","year":"2024","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jlr.2025.100835_bib19","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/s41564-020-0781-2","article-title":"Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion","volume":"5","author":"Ma","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.jlr.2025.100835_bib20","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s12325-016-0407-5","article-title":"A review of daclatasvir drug-drug interactions","volume":"33","author":"Garimella","year":"2016","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jlr.2025.100835_bib21","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s40265-016-0632-x","article-title":"Daclatasvir: a review in chronic hepatitis C","volume":"76","author":"Keating","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.jlr.2025.100835_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg8116","article-title":"A small molecule targeting ALOX12-ACC1 ameliorates nonalcoholic steatohepatitis in mice and macaques","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jlr.2025.100835_bib23","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(24)01811-7","article-title":"Steatotic liver disease","volume":"404","author":"Israelsen","year":"2024","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.jlr.2025.100835_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ade7347","article-title":"Multispecies transcriptomics identifies SIKE as a MAPK repressor that prevents NASH progression","volume":"16","author":"Bai","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jlr.2025.100835_bib25","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1074\/jbc.RA118.005556","article-title":"N-terminal acetylation and the N-end rule pathway control degradation of the lipid droplet protein PLIN2","volume":"294","author":"Nguyen","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jlr.2025.100835_bib26","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/jcsm.13233","article-title":"Identification of Ubr1 as an amino acid sensor of steatosis in liver and muscle","volume":"14","author":"Zhao","year":"2023","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jlr.2025.100835_bib27","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3390\/cells8030252","article-title":"Hepatitis C direct acting antivirals and ribavirin modify lipid but not glucose parameters","volume":"8","author":"Doyle","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.jlr.2025.100835_bib28","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/apt.14218","article-title":"Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers","volume":"46","author":"Shaheen","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"Suppl 1","key":"10.1016\/j.jlr.2025.100835_bib29","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1478-3231.2010.02411.x","article-title":"New direct-acting antivirals\u2019 combination for the treatment of chronic hepatitis C","volume":"31","author":"Asselah","year":"2011","journal-title":"Liver Int."},{"key":"10.1016\/j.jlr.2025.100835_bib30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/1060028015610342","article-title":"Daclatasvir: a NS5A replication complex inhibitor for hepatitis C infection","volume":"50","author":"Smith","year":"2016","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.jlr.2025.100835_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28501","article-title":"Impact of nonalcoholic fatty liver disease status change on antiviral efficacy of nucleos(t)ide analogues in HBeAg-positive chronic hepatitis B","volume":"95","author":"Tang","year":"2023","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.jlr.2025.100835_bib32","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/gutjnl-2019-318372","article-title":"Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells","volume":"69","author":"Mart\u00ed-Rodrigo","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jlr.2025.100835_bib33","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/s41586-023-06401-0","article-title":"TRIM5\u03b1 restricts poxviruses and is antagonized by CypA and the viral protein C6","volume":"620","author":"Zhao","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jlr.2025.100835_bib34","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.antiviral.2013.09.020","article-title":"Host-targeting agents in the treatment of hepatitis C: a beginning and an end?","volume":"100","author":"Baugh","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jlr.2025.100835_bib35","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/j.devcel.2023.07.001","article-title":"Parallel CRISPR-Cas9 screens identify mechanisms of PLIN2 and lipid droplet regulation","volume":"58","author":"Roberts","year":"2023","journal-title":"Dev. Cell"},{"key":"10.1016\/j.jlr.2025.100835_bib36","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1038\/s41418-022-01018-8","article-title":"Plin2-mediated lipid droplet mobilization accelerates exit from pluripotency by lipidomic remodeling and histone acetylation","volume":"29","author":"Wu","year":"2022","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.jlr.2025.100835_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2024.100635","article-title":"Therapeutic siRNA targeting PLIN2 ameliorates steatosis, inflammation, and fibrosis in steatotic liver disease models","volume":"65","author":"Wang","year":"2024","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jlr.2025.100835_bib38","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1080\/15548627.2017.1319544","article-title":"The constitutive lipid droplet protein PLIN2 regulates autophagy in liver","volume":"13","author":"Tsai","year":"2017","journal-title":"Autophagy"},{"key":"10.1016\/j.jlr.2025.100835_bib39","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s41048-019-0091-5","article-title":"Perilipin 2 and lipid droplets provide reciprocal stabilization","volume":"5","author":"Xu","year":"2019","journal-title":"Biophys. Rep."},{"key":"10.1016\/j.jlr.2025.100835_bib40","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jhep.2023.12.029","article-title":"TRIB3\u2013TRIM8 complex drives NAFLD progression by regulating HNF4\u03b1 stability","volume":"80","author":"Xiao","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jlr.2025.100835_bib41","doi-asserted-by":"crossref","DOI":"10.1172\/JCI166149","article-title":"TRIM56 protects against nonalcoholic fatty liver disease by promoting the degradation of fatty acid synthase","volume":"134","author":"Xu","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jlr.2025.100835_bib42","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1002\/hep.32061","article-title":"The E3 ubiquitin ligase ring finger protein 5 ameliorates NASH through ubiquitin-mediated degradation of 3-hydroxy-3-methylglutaryl CoA reductase degradation protein 1","volume":"74","author":"Yang","year":"2021","journal-title":"Hepatology"}],"container-title":["Journal of Lipid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227525000951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227525000951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T21:57:50Z","timestamp":1762207070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022227525000951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0022227525000951"],"URL":"https:\/\/doi.org\/10.1016\/j.jlr.2025.100835","relation":{},"ISSN":["0022-2275"],"issn-type":[{"value":"0022-2275","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatoprotective drug screening identifies daclatasvir, a promising therapeutic candidate for MASLD by targeting PLIN2","name":"articletitle","label":"Article Title"},{"value":"Journal of Lipid Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jlr.2025.100835","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology\u00e9","name":"copyright","label":"Copyright"}],"article-number":"100835"}}